Payment overview · 2025
General Payments
$1,288.88
55 reported records · 18 companies
Healthcare provider profile · identity verified
Joseph S Peyton, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MAUMEE, OH · NPI 1538145925
Verified facts
What the public records show
CMS Open Payments records show Joseph S Peyton, D.O. received $1,288.88 in general payments during 2025 across 55 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Lokelma, Mounjaro, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Lokelma by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 915 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $308.34 | 23.9% | 13 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $258.22 | 20.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $148.10 | 11.5% | 10 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $138.28 | 10.7% | 7 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $80.74 | 6.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $70.26 | 5.5% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.22 | 2.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.33 | 2.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.87 | 2.6% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.03 | 2.6% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.63 | 2.2% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$24.04 | 1.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.66 | 1.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.63 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.02 | 1.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.97 | 1.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.83 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.71 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,134.89 | 53 |
| Education | $153.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $218.36 | 14 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $173.32 | 11 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $138.28 | 7 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $136.36 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $136.36 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $121.86 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $80.74 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.22 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.33 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $33.03 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $28.63 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
86 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
915 | 97 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1067 | 210 |
| Furosemide | Furosemide | 943 | 149 |
| Eliquis | Apixaban | 915 | 97 |
| Potassium Chloride | Potassium Chloride | 850 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 845 | 120 |
| Omeprazole | Omeprazole | 666 | 103 |
| Sertraline Hcl | Sertraline Hcl | 631 | 94 |
| Gabapentin | Gabapentin | 578 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 552 | 110 |
| Buspirone Hcl | Buspirone Hcl | 506 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 505 | 100 |
| Divalproex Sodium | Divalproex Sodium | 489 | 67 |
| Quetiapine Fumarate | Quetiapine Fumarate | 485 | 67 |
| Trazodone Hcl | Trazodone Hcl | 485 | 86 |
| Metoprolol Tartrate | Metoprolol Tartrate | 466 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 466 | 84 |
| Donepezil Hcl | Donepezil Hcl | 451 | 74 |
| Metformin Hcl | Metformin Hcl | 409 | 68 |
| Lisinopril | Lisinopril | 398 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 395 | 69 |
| Bumetanide | Bumetanide | 385 | 58 |
| Losartan Potassium | Losartan Potassium | 378 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 286 | 47 |
| Mirtazapine | Mirtazapine | 284 | 58 |
| Memantine Hcl | Memantine Hcl | 283 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 271 | 49 |
| Levetiracetam | Levetiracetam | 270 | 38 |
| Warfarin Sodium | Warfarin Sodium | 255 | 20 |
| Spironolactone | Spironolactone | 250 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 245 | 36 |
| Carvedilol | Carvedilol | 238 | 52 |
| Olanzapine | Olanzapine | 217 | 29 |
| Xarelto | Rivaroxaban | 205 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 200 | 46 |
| Simvastatin | Simvastatin | 194 | 34 |
| Famotidine | Famotidine | 185 | 43 |
| Risperidone | Risperidone | 182 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 29 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 175 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 171 | 24 |
| Myrbetriq | Mirabegron | 160 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 158 | 24 |
| Prednisone | Prednisone | 157 | 55 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 156 | 28 |
| Topiramate | Topiramate | 156 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 150 | 21 |
| Ibuprofen | Ibuprofen | 148 | 33 |
| Lamotrigine | Lamotrigine | 145 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 140 | 61 |
| Baclofen | Baclofen | 130 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 33 |
| Aripiprazole | Aripiprazole | 119 | 20 |
| Midodrine Hcl | Midodrine Hcl | 119 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 17 |
| Allopurinol | Allopurinol | 114 | 22 |
| Albuterol Sulfate | Albuterol Sulfate | 113 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 36 |
| Atenolol | Atenolol | 109 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 107 | 22 |
| Cephalexin | Cephalexin | 106 | 52 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 105 | 21 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 102 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 99 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 27 |
| Januvia | Sitagliptin Phosphate | 97 | 13 |
| Latanoprost | Latanoprost | 97 | 29 |
| Finasteride | Finasteride | 95 | 18 |
| Enulose | Lactulose | 94 | 13 |
| Montelukast Sodium | Montelukast Sodium | 93 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 26 |
| Meloxicam | Meloxicam | 90 | 16 |
| Jardiance | Empagliflozin | 88 | 14 |
| Lorazepam | Lorazepam | 88 | 37 |
| Trulicity | Dulaglutide | 86 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 83 | suppressed |
| Metolazone | Metolazone | 82 | 16 |
| Bupropion Xl | Bupropion Hcl | 81 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 81 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 80 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 80 | 11 |
| Azithromycin | Azithromycin | 78 | 44 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 78 | 14 |
| Amantadine | Amantadine Hcl | 76 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 37 |
| Carbamazepine Er | Carbamazepine | 75 | suppressed |
| Glipizide | Glipizide | 75 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 73 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 20 |
| Celecoxib | Celecoxib | 71 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 71 | 15 |
| Ezetimibe | Ezetimibe | 70 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 16 |
| Metformin Hcl Er | Metformin Hcl | 69 | suppressed |
| Rivastigmine | Rivastigmine | 66 | 17 |
| Loperamide | Loperamide Hcl | 63 | 33 |
| Nystatin | Nystatin | 63 | 31 |
| Novolog Flexpen | Insulin Aspart | 62 | 14 |
| Sucralfate | Sucralfate | 62 | suppressed |
| Clozapine | Clozapine | 61 | suppressed |
| Naproxen | Naproxen | 61 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 60 | suppressed |
| Lactulose | Lactulose | 60 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 34 |
| Levofloxacin | Levofloxacin | 59 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | suppressed |
| Nifedipine Er | Nifedipine | 54 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 53 | 11 |
| Torsemide | Torsemide | 53 | suppressed |
| Methotrexate | Methotrexate Sodium | 52 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 52 | suppressed |
| Glimepiride | Glimepiride | 51 | suppressed |
| Haloperidol | Haloperidol | 51 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 51 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 50 | suppressed |
| Hydrocortisone | Hydrocortisone | 50 | 15 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 48 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 48 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 47 | suppressed |
| Alprazolam | Alprazolam | 46 | 12 |
| Invega Sustenna | Paliperidone Palmitate | 46 | suppressed |
| Lovastatin | Lovastatin | 46 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 28 |
| Nyamyc | Nystatin | 44 | 32 |
| Venlafaxine Hcl | Venlafaxine Hcl | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Acetylcysteine | Acetylcysteine | 42 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 38 | suppressed |
| Tradjenta | Linagliptin | 37 | suppressed |
| Brilinta | Ticagrelor | 36 | suppressed |
| Digoxin | Digoxin | 36 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 36 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 36 | 13 |
| Ziprasidone Hcl | Ziprasidone Hcl | 36 | suppressed |
| Cilostazol | Cilostazol | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 25 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Paliperidone Er | Paliperidone | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 32 | suppressed |
| Timolol Maleate | Timolol Maleate | 32 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Budesonide | Budesonide | 30 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Novolog | Insulin Aspart | 30 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 21 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Acarbose | Acarbose | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Folic Acid | Folic Acid | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | suppressed |
| Dexilant | Dexlansoprazole | 26 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 26 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 25 | 25 |
| Dutasteride | Dutasteride | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 22 |
| Nitroglycerin Patch | Nitroglycerin | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Restasis | Cyclosporine | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Cyclosporine | Cyclosporine | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 20 |
| Fiasp | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Dexamethasone | Dexamethasone | 22 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Nystop | Nystatin | 21 | 14 |
| Bethanechol Chloride | Bethanechol Chloride | 20 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 20 | 12 |
| Ertapenem | Ertapenem Sodium | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 20 | suppressed |
| Risperidone Odt | Risperidone | 20 | suppressed |
| Scopolamine | Scopolamine | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Azathioprine | Azathioprine | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Cimetidine | Cimetidine | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | 13 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Roflumilast | Roflumilast | 18 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Droxidopa | Droxidopa | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 15 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 15 | suppressed |
| Galantamine Er | Galantamine Hbr | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Trimethoprim | Trimethoprim | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Cyclosporine Modified | Cyclosporine, Modified | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 13 | 11 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Acetic Acid | Acetic Acid | 12 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,288.88 · 55 records | Teva Pharmaceuticals USA, Inc. | AFREZZA, AUSTEDO XR, CAPLYTA, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, EVENITY, FANAPT, INGREZZA, LOKELMA, MOUNJARO, NURTEC ODT, REXULTI, SHINGRIX, UZEDY, VOQUEZNA, VOWST, WATCHMAN Access System, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Lokelma play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error